Search results
HC Wainwright Reiterates “Buy” Rating for BioLineRx (NASDAQ:BLRX)
ETF DAILY NEWS· 5 days agoBioLineRx (NASDAQ:BLRX – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have ...
Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
BioPharma Dive via Yahoo Finance· 2 days agoNonetheless, several have drawn the interest of large pharmaceutical companies. Ipsen, for instance,...
Why Is Bio-Path (BPTH) Stock Up 89% Today?
InvestorPlace· 6 days agoBio-Path (NASDAQ:BPTH) stock is rising higher on Thursday after the oncology company announced an update on its Phase 1/1b clinical trial of BP1002. This...
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy
Market Watch· 2 days agoThe San Diego-based biopharmaceutical company said the U.S. Food and Drug Administration had granted ziftomenib the status as a potential treatment for relapsed/refractory NPM1-mutant
I left my daughter's dad 4 years ago and have zero interest in reentering the dating world
INSIDER via Yahoo News· 2 days agoWhen she was six months old, I asked him to leave. During those tough months, doctors diagnosed my...
Wiregrass teen battling cancer and rare kidney disease passes away
WDHN Dothan via Yahoo News· 1 day ago(WDHN) — A Wiregrass teen, who for the past year has been battling cancer and a rare kidney disease,...
Why Bio-Path Stock Is Soaring - Bio-Path Hldgs (NASDAQ:BPTH)
Benzinga· 6 days agoBPTH shares are trading higher Thursday after the company announced the completion of its second...
Chandler community rallying around toddler who needs life-saving bone marrow transplant
KTVK 3TV Phoenix· 3 days agoFamily and friends are rallying around a toddler who is battling cancer, hoping he will soon receive...
Central Mass. by the Numbers
Worcester Telegram & Gazette via Yahoo News· 3 days agoDavis' son, Larry, said the cause was acute myeloid leukemia. Davis and his sons, Larry and Doug, developed the idea of a petting zoo ...
Aileron Therapeutics (NASDAQ:ALRN) Price Target Raised to $19.00 at LADENBURG THALM/SH SH
ETF DAILY NEWS· 5 days agoAileron Therapeutics (NASDAQ:ALRN – Free Report) had its price target lifted by LADENBURG THALM/SH SH from $9.00 to $19.00 in a research report released on Thursday morning, Benzinga reports ...
